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Abstract
Background: N-Hydroxyphthalimide (NHPI), an important chemical raw material, was found to have potent and
selective anti-proliferative effect on human breast carcinoma BT-20 cells, human colon adenocarcinoma LoVo and
HT-29 cells during our screening for anticancer compounds. The purpose of this study is to assess the antitumor
efficacy of NHPI in vitro and in vivo and to explore the underlying antitumor mechanism.
Methods: Cell cytotoxicity of NHPI was evaluated using MTS assay and cell morphological analysis. After NHPI
treatment, cell cycle, apoptosis and mitochondrial membrane potential were analyzed using flow cytometer. The
subcellular localization of eukaryotic initiation factor 4E (eIF4E) was analyzed by immunofluorescence assay. The
antitumor efficacy of NHPI in vivo was tested in BT-20 xenografts. The underlying antitumor mechanisms of NHPI
in vitro and in vivo were investigated with western blot analysis in NHPI-treated cancer cells and tumor tissues.
Statistical significance was determined using Student’s t-test.
Results: In vitro, NHPI selectively inhibited the proliferation and induced G2/M phase arrest in BT-20 and LoVo cells,
which was attributed to the inhibition of cyclin B1 and cdc2 expressions. Furthermore, NHPI induced apoptosis via
mitochondrial pathway. Of note, NHPI effectively inhibited mammalian target of rapamycin (mTOR) complex 1
(mTORC1) and mTOR complex 2 (mTORC2) signaling, and overcame the feedback activation of Akt and extracellular
signal-regulated kinase (ERK) caused by mTORC1 inhibition in BT-20 and LoVo cells. In vivo, NHPI inhibited tumor
growth and suppressed mTORC1 and mTORC2 signaling in BT-20 xenografts with no obvious toxicity.
Conclusions: We found for the first time that NHPI displayed antitumor activity which is associated with the
inhibition of mTOR signaling pathway. Our findings suggest that NHPI may be developed as a promising candidate
for cancer therapeutics by targeting mTOR signaling pathway and as such warrants further exploration.
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Background
Mammalian target of rapamycin (mTOR) is an atypical
serine/threonine kinase that belongs to the phosphoino-
sitide 3-kinase (PI3K)-related kinase family [1]. The
mTOR kinase exists and acts as the catalytic subunit in
two functionally and structurally distinct multi-protein
complexes: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2) [2, 3]. The mTOR signaling path-
way integrates both intracellular and extracellular signals
and serves as a central regulator of cell metabolism,
growth, proliferation and survival [1, 4]. The activation
of mTORC1 leads to phosphorylation of ribosomal S6
protein kinase 1 (S6K1) and translational repressor
eukaryotic initiation factor 4E (eIF4E)-binding protein 1
(4E-BP1), thus modulating ribosome biogenesis and the
translation of proteins that promote cell growth [5].
S6K1 phosphorylates ribosomal protein S6 (S6) and en-
hances the translation of mRNAs [1, 6]. S6K1 also phos-
phorylates other important targets, including insulin
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receptor substrate 1 (IRS-1), eukaryotic initiation factor
4B, programmed cell death 4, eukaryotic elongation
factor-2 kinase and mTOR [6]. Phosphorylation of 4E-
BP1 releases its inhibitory effect on eIF4E, promoting
cap-dependent mRNA translation [7]. eIF4E enhances
cell growth, proliferation, survival and angiogenesis by
selectively translating mRNA such as cyclin D1, Bcl-2,
Bcl-xL and vascular endothelial growth factor [8, 9].
mTORC2 regulates cell survival by phosphorylating on
Ser473 of Akt, also known as protein kinase B, which is
one of the most important survival kinases [1, 10].
Consistent with a critical role in regulating cell growth
and metabolism, dysregulation of the mTOR signaling is
commonly observed in human cancers [11–14]. Aberrant
mTOR signaling pathway activation through oncogene
stimulation or loss of tumor suppressors contributes signifi-
cantly to cancer initiation, development and chemotherapy
resistance [1, 7, 11, 14–18]. Cumulative evidence indicates
that mTOR signaling pathway has become an attractive tar-
get for cancer therapy and targeting mTOR signaling has
been exploited as a promising tumor-selective therapeutic
strategy [11, 12, 19, 20]. The most well-characterized inhibi-
tors targeting this pathway are rapamycin and its analogs
(also referred as rapalogs), which are currently used with
success for treating certain types of tumors [21, 22]. How-
ever, rapalogs incompletely inhibit mTORC1 and generally
fail to inhibit mTORC2 in some tumor types, which may
not be sufficient for achieving a robust anticancer effect
[15, 21, 23, 24]. Moreover, resistance to treatment with
rapalogs has been reported. The resistance may be associ-
ated with disrupting the mTORC1-mediated negative feed-
back loops to IRS-1/PI3K, mTORC2 and mitogen-activated
protein kinase (MAPK)/extracellular signal-regulated kinase
(ERK), which lead to activation of Akt and MAPK/ERK
signaling, thereby, counteracting the antitumor poten-
tial of mTORC1 inhibition [24–27]. These insights
have prompted the development of potent mTOR
signaling inhibitors capable of overcoming the feedback
activation of several oncogenic pathways and fully inhi-
biting the function of both mTOR complexes.
In the present study, N-Hydroxyphthalimide (NHPI),
an important chemical raw material, was found to have
potent and selective anti-proliferative effect on human
breast carcinoma BT-20 cells, human colon adenocarcin-
oma LoVo and HT-29 cells during our screening for an-
ticancer compounds. In vitro, NHPI induced G2/M
phase arrest in BT-20 and LoVo cells, which was attrib-
uted to the inhibition of cyclin B1 and cdc2 expressions.
Moreover, NHPI induced apoptosis via mitochondrial
pathway. Of note, NHPI effectively inhibited mTORC1
and mTORC2 signaling in BT-20 and LoVo cells, negat-
ing the feedback activation of Akt and ERK caused by
mTORC1 inhibition. In vivo, NHPI significantly inhib-
ited tumor growth and suppressed mTORC1 and
mTORC2 signaling in BT-20 xenografts with no obvious
toxicity. These findings suggest that NHPI may be a po-
tential candidate for cancer therapeutics by targeting




N-Hydroxyphthalimide was purchased from Accela
ChemBio Co., Ltd. (Shanghai, China). Propidium iodide
(PI), RNase A and 4,6-diamidino-2-phenylindole (DAPI)
were from Sigma-Aldrich. Antibodies of mTOR,
Phospho-mTOR (Ser2448), Phospho-mTOR (Ser2481),
S6K1, Phospho-S6K1 (Thr389), Phospho-S6 Ribosomal
Protein (Ser235/236), 4E-BP1, Phospho-4E-BP1 (Ser65),
Phospho-Akt (Ser473), Phospho-Akt (Thr308), Cleaved
PARP, Cleaved Caspase 3, Caspase 9, cyclin B1, cdc2
were obtained from Cell Signaling Technology; anti-
bodies of S6, Akt, P-ERK1/2, β-actin, Caspase 3, Caspase
8, Bcl-xL, survivin were from Santa Cruz; antibody of
ERK was from Epitomics; antibody of eIF4E was ob-
tained from BD Biosciences; Alexa Fluor® 647 donkey
anti-mouse IgG antibody was purchased from Invitro-
gen; all the other secondary antibodies were from
Sigma-Aldrich.
Cell culture
Human breast carcinoma cell line BT-20 and human
normal breast epithelial cell line MCF-10A were pur-
chased from Cell Research Center, IBMS, CAMS/PUMC
(Beijing, China). Human breast cancer cell lines SK-BR-
3, MDA-MB-231, MDA-MB-468, MDA-MB-436,
HCC1937 and MCF7, human colon cancer cell lines
LoVo, HT-29, Caco-2 and RKO, human leukemia cell
lines Jurkat, HL-60 and K-562, human ovary adenocar-
cinoma cell line NIH:OVCAR-3 and human hepatocellu-
lar carcinoma cell line SMMC-7721 were purchased
from Cell Bank of Type Culture Collection of Chinese
Academy of Sciences (Shanghai, China). All cells were
cultured according to the vendor’s instructions.
Cell viability assay
Cell viability was determined by MTS assay, according
to the protocol of CellTiter 96®AQueous One Solution
Cell Proliferation Assay kit (Promega). Briefly, 100 μl of
cell suspensions were seeded into each well of 96-well
plates at a density of 5 × 103 cells/well and cultured over-
night. Cells were then exposed to the tested compounds
in triplicates for 48 h, 20 μL of CellTiter 96®AQueous
One Solution Reagent was added to each well, and the
cells were further incubated at 37 °C for 1–2 h. Cell via-
bility was detected by measuring the optical density
(OD) at 490 nm using a microplate reader (Bio-Rad
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Laboratories). The half inhibitory concentration (IC50)
was determined by the relative survival curve.
Cell morphological analysis
Cells were seeded in 6-well plates (4 × 105 cells/well) and
grown overnight. Next day, the cells were treated with
indicated concentrations of NHPI. After incubation for
24 h, the morphology of cells was observed using a
phase-contrast microscope (Eclipse Ti, Nikon) at 100×
magnification.
Cell cycle analysis
Cells were seeded in 6-well plates and incubated at 37 °C
overnight. Cells were then treated with indicated con-
centrations of NHPI for 24 h. Subsequently, the cells
were collected and fixed with pre-cold 70 % ethanol
overnight at −20 °C. Fixed cells were washed with
PBS and incubated with a staining solution containing
RNase A and PI in PBS for 30 min at room
temperature. Fluorescence intensity was analyzed by
FACSCalibur flow cytometer (BD Biosciences). The
distribution of cells in each phase of the cell cycle
was determined using FlowJo7.6.1 analysis software.
Apoptosis assay
Cell apoptosis was analyzed using the Annexin V-FITC
Apoptosis Detection Kit I (BD Biosciences) according to
the manufacturer’s protocol. Cells were seeded in 6-well
plates at a density of 1 × 105 cells/well and incubated
overnight. After indicated treatment, cells were collected
and washed twice with cold PBS, then resuspended in a
binding buffer containing Annexin V-FITC and PI. After
incubation for 15 min at room temperature in the dark,
the fluorescence intensity was measured using a FACS-
Calibur flow cytometer (BD Biosciences).
Protein extraction and western blot analysis
Cells were seeded in 6-well plates at a density of 4 × 105
cells/well. The next day, cells were treated with indicated
concentrations of NHPI for 24 h. Following treatment,
cells were washed with cold PBS. On ice, cells were lysed
in RIPA buffer, containing 50 mM Tris, pH 7.4; 150 mM
NaCl; 1 % sodium deoxycholate; 0.1 % sodium dodecyl
sulfate; 1 % NP-40; 1 mM EDTA; 1 mM PMSF; protease
and phosphatase inhibitor cocktail (Roche). Lysates were
centrifuged, and the supernatant was dissolved with 5×
sample loading buffer and boiled for 5 min. Protein ex-
tracts were quantitated and loaded on 8–12 % sodium
dodecyl sulfate polyacrylamide gel, electrophoresed and
transferred to polyvinylidene fluoride membranes (Milli-
pore). Membranes were incubated with 5 % non-fat dry
milk to block non-specific binding and were incubated
with primary antibodies, then with appropriate second-
ary antibodies conjugated to horseradish peroxidase.
Proteins of interest were incubated with Pierce ECL sub-
strate (Thermo Scientific) and visualized by chemilumin-
escent detection on an ImageQuant LAS 4000 mini (GE
Healthcare).
Mitochondrial membrane potential assay
The mitochondria membrane potential (MMP) in BT-20
cells was measured using JC-1 Mitochondrial Membrane
Potential Assay Kit (Cayman Chemical Company).
Briefly, BT-20 cells were seeded in 6-well plates at a
density of 2 × 105 cells/well and incubated overnight for
cell attachment. Cells were then treated with indicated
concentrations of NHPI. After 48 h, added 200 μl of the
JC-1 Staining Solution (1:10 dilution in culture medium)
into each well and incubated for 30 min at 37 °C in a
CO2 incubator. Next, the cells were trypsinized and col-
lected. The samples were analyzed immediately using a
FACSCalibur flow cytometer (BD Biosciences).
Immunofluorescence assay
BT-20 cells were seeded and cultured in 96-well plates
(1 × 104 cells/well) overnight and then treated with indi-
cated concentrations of NHPI. After incubation for 6 h,
cells were fixed with 4 % paraformaldehyde for 20 min,
and the fixed cells were permeabilized with 0.1 % Triton
X-100 for 10 min. After blocking with 2 % BSA at 37 °C
for 30 min, cells were incubated with eIF4E antibody
(1:400 in 2 % BSA) at 4 °C overnight and then the cells
were incubated with Alexa Fluor® 647 donkey anti-
mouse IgG antibody (1:1000 in 2 % BSA) for 1 h at room
temperature. DAPI was used to stain the nuclei. To
monitor the subcellular location of eIF4E, Cellomics®
ArrayScan® VTI HCS Reader (Thermo Scientific) was
used to capture the images.
In vivo studies
Three-week old female BALB/c nude mice were pur-
chased from Vital River Laboratory Animal Technology
(Beijing, China) and fed in a specific pathogen-free en-
vironment and treated in accordance with the guidelines
of the Animal Ethics Committee of Kunming Institute of
Botany (Kunming, China). 6.8 × 106 BT-20 cells in
Matrigel (Corning) were subcutaneously implanted into
the right flank of nude mice for tumor formation.
Tumor size was measured every three days in two di-
mensions with a digital caliper and calculated using the
formula (length × width × width × 0.5). When the tumor
reached approximately 100 mm3, mice were randomly
divided into the control and treatment groups (n = 9/
group). Subsequently, mice were treated daily by intra-
peritoneal injection with NHPI (40 mg/kg) prepared in a
solution (10 % ethanol and 30 % PEG 400 in sterile sa-
line) or vehicle control. At the end of treatment, mice
were sacrificed and tumors were removed from mice.
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Then the tumors were weighed and frozen immediately
at −80 °C for subsequent western blot analysis. Tumor
samples were minced and homogenized to extract whole
cell lysates. The clarified supernatants of the samples
were applied for western blot analysis using specific
antibodies.
Statistical analysis
Results in in vivo studies were expressed as mean ±
standard error (mean ± SE) and all the other results were
expressed as mean ± standard deviation (mean ± SD).
The data were analyzed using Student’s t-test. A prob-
ability value of P < 0.05 was considered to be statistically
significant.
Results
Cytotoxicity of NHPI toward tumor cells
During the screening for anticancer compounds, NHPI
(Fig. 1a) was found to have potent and selective cytotox-
icity against human breast carcinoma BT-20 cells, hu-
man colon adenocarcinoma LoVo and HT-29 cells
(Fig. 1b). The anti-proliferative effect of NHPI on these
three cancer cell lines and human normal breast epithe-
lial MCF-10A cells was further tested using MTS assay
by treating the cells with different concentrations of
NHPI. As shown in Fig. 2a, treatment with NHPI
(0–40 μM) for 48 h inhibited the proliferation of BT-20,
LoVo and HT-29 cells in a concentration-dependent man-
ner. IC50 value of NHPI on the proliferation of these three
cancer cell lines was 3.14 ± 0.06 μM, 4.05 ± 0.12 μM and
11.54 ± 0.12 μM, respectively (Fig. 2b). Of note, NHPI did
not affect the proliferation of human normal breast epi-
thelial MCF-10A cells. Morphological changes were then
observed in these cell lines after incubation with indicated
concentrations of NHPI for 24 h. As illustrated in Fig. 2c,
BT-20, LoVo and HT-29 cells exposed to NHPI exhibited
distinct cell shrinkage and rounded shapes in a
concentration-dependent manner. However, NHPI did not
affect the morphology of human normal breast epithelial
MCF-10A cells. Taken together, NHPI selectively inhibited
the proliferation of BT-20, LoVo and HT-29 cells, suggest-
ing that NHPI could be a promising anticancer agent for
human breast carcinoma and human colon adenocarcin-
oma selective treatment.
NHPI induces G2/M phase cell cycle arrest by inhibiting
the expressions of cyclin B1 and cdc2
Cell proliferation is controlled by the progression of the
cell cycle [28]. To understand how NHPI inhibited cell
proliferation, we assessed the effect of NHPI on cell
cycle distribution using PI staining and flow cytometry.
As shown in Fig. 3a, both BT-20 and LoVo cells were
arrested in G2/M phase after incubation with various
concentrations of NHPI for 24 h, especially at the high
concentration. The percent of cells in the G2/M fraction
significantly increased compared with the control ac-
companied by a decrease of cell number in S phase of
the cell cycle (Fig. 3b).
To further understand the mechanism for NHPI-
induced G2/M phase cell cycle arrest, the expression
levels of key regulators of cell cycle were examined. Cyc-
lin B1 and cdc2 (CDK1) are two key regulators for G2 to
M phase transition [29]. As shown in Fig. 3c, treatment
of BT-20 and LoVo cells with NHPI for 24 h repressed
cellular protein expressions of cyclin B1 and cdc2 in a
concentration-dependent manner. Taken together, these
results demonstrate that NHPI arrests BT-20 and LoVo
cells in G2/M phase of cell cycle in a concentration-
dependent manner, with the involvement of decreasing
the expressions of cyclin B1 and cdc2.
NHPI induces apoptosis via mitochondrial pathway
To determine whether the anti-proliferative effect of
NHPI was associated with the induction of apoptosis,
the Annexin V-FITC/PI double staining and flow cytom-
etry analysis were used to analyze apoptosis parameter.
The late and early apoptotic cells, which are shown, re-
spectively, in the upper right and lower right quadrants
Fig. 1 NHPI selectively decreases cell viability in BT-20, LoVo and
HT-29 cells. a Chemical structure of NHPI. b All the tested cancer cells
were treated with 40 μM NHPI for 48 h. Cell viability was determined
by MTS assay and represented with relative viability versus control.
Results were presented as mean ± SD (n = 3)
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of the dot plot, were counted as apoptotic cells. As
shown in Fig. 4a, treatment of BT-20 cells with NHPI
for 48 h increased the percentage of apoptotic cells in a
concentration-dependent manner. When BT-20 cells
were treated with NHPI at 10 μM, the total percentage
of apoptotic cells increased about 8.8-fold compared
with the vehicle control (Fig. 4b). Treatment of LoVo
cells with NHPI increased the percentage of apoptotic
cells in a concentration-and time-dependent manner
(Fig. 4a and b).
Intrinsic apoptosis is also known as mitochondrial
apoptosis because it depends on factors released from
the mitochondria [30]. The mitochondrion-mediated
pathway begins with the loss of mitochondrial mem-
brane potential (MMP) [31, 32]. To determine whether
MMP change was involved in NHPI-induced apoptosis,
MMP change was measured by JC-1 staining. BT-20
cells were treated with NHPI for 48 h, stained with JC-1
and subjected to flow cytometry analysis. JC-1 forms ag-
gregates, which emit red fluorescence in the mitochon-
dria of healthy cells. However, it remains as monomers
that exhibit green fluorescence during the loss of MMP.
As shown in Fig. 4c and d, treatment of BT-20 cells with
NHPI resulted in a significant increase of JC-1 mono-
mers and a significant decrease of JC-1 aggregates,
indicating that NHPI induced MMP loss in a
concentration-dependent manner.
Apoptosis is also known as programmed cell death
and caspases are the major executioners of apoptosis.
Among the members of the caspase family, caspase-9 is
the essential initiator required for mitochondrial apop-
tosis pathway [30, 33]. The mitochondrial pathway is
regulated by the Bcl-2 family members which has both
anti-apoptotic (Bcl-2 and Bcl-xL) and pro-apoptotic
(Bax, Bad and Bid) proteins [34, 35]. To investigate the
mechanism by which NHPI induced apoptosis, the ex-
pressions of apoptosis-related proteins were tested by
western blot analysis. As shown in Fig. 4e, treatment of
BT-20 cells with NHPI for 24 h induced a decline in
anti-apoptotic proteins survivin and Bcl-xL as well as
the activation of caspase 9 and caspase 3, but not cas-
pase 8. In addition, NHPI increased the level of poly
Fig. 2 NHPI concentration-dependently decreases cell viability in BT-20, LoVo and HT-29 cells. a BT-20, LoVo, HT-29 and MCF-10A cells were treated
with indicated concentrations of NHPI for 48 h. Cell viability was determined by MTS assay and represented with relative viability versus control. Results
were presented as mean ± SD (n= 3). b IC50 values of NHPI on cell proliferation were shown with mean ± SD (n = 3). c The morphology of BT-20, LoVo,
HT-29 and MCF-10A cells treated with NHPI at 5 and 10 μM for 24 h were observed under a phase-contrast microscope and photographed (100×)
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ADP-ribosepolymerase (PARP) cleavage, a known cellu-
lar substrate of caspases that plays vital role in apoptosis
(Fig. 4e) [36]. Taken together, the above results suggest
that NHPI induces apoptosis via mitochondrial pathway
in BT-20 cells.
NHPI inhibits both mTORC1 and mTORC2 signaling in
BT-20 and LoVo cells
The mTOR signaling pathway is pivotal in regulating
major cell functions including cell growth, prolifera-
tion and survival [1, 4]. In our study, NHPI was
found to selectively inhibit the proliferation and in-
duced apoptosis in BT-20 and LoVo cells. We hy-
pothesized that NHPI might be disrupting these
cellular processes by primarily repressing the mTOR
signaling pathway. To test this hypothesis, we set
out to examine the effect of NHPI on mTOR signal-
ing pathway in BT-20, LoVo and MDA-MB-231 cells.
By western blot analysis, we found that NHPI inhib-
ited phosphorylation of S6K1 and 4E-BP1, two best
characterized direct substrates of mTORC1 [37], in a
concentration-dependent manner in BT-20 and LoVo
cells (Fig. 5a). Consistently, NHPI suppressed phos-
phorylation of S6, a substrate of S6K1 as well
(Fig. 5a). Interestingly, NHPI at high concentration
(40 μM) neither affected the cell viability nor inhib-
ited mTORC1 signaling in MDA-MB-231 cells
(Figs. 1b and 5a). The above data suggest that NHPI
inhibits cell proliferation, at least in part, by disrupt-
ing the mTOR signaling pathway.
Fig. 3 NHPI induces G2/M phase cell cycle arrest by inhibiting the expressions of cyclin B1 and cdc2. a BT-20 cells were treated with NHPI at 2.5,
5 and 10 μM for 24 h. LoVo cells were incubated with NHPI at 5, 10 and 15 μM for 24 h. Cells were stained with PI and subjected to flow cytometry
analysis. Representative images were shown. b Quantitative analysis of cells in each cell cycle phase was performed. Results were presented
as mean ± SD (n = 3). *p < 0.05 and ***p <0.001, difference versus 0 μM control group. c The inhibition of cyclin B1 and cdc2 expressions
contributed to NHPI-induced G2/M phase arrest. Cells were treated with indicated concentrations of NHPI for 24 h, and the expression levels
of G2/M phase regulatory proteins were analyzed by western blot analysis. β-actin was used as a loading control
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In addition, NHPI restrained phosphorylation of
mTOR at Ser2448, a site phosphorylated by S6K1 [38],
in a concentration-dependent manner in BT-20 and
LoVo cells (Fig. 5b). Because Akt phosphorylation by
PI3K is crucial for cell proliferation, growth and survival,
we examined whether the PI3K site on Akt (Thr308)
was also affected by NHPI. As shown in Fig. 5b, NHPI
dramatically curbed PI3K-mediated Akt phosphorylation
Fig. 4 NHPI induces apoptosis via mitochondrial pathway. a BT-20 cells were treated with NHPI at 2.5, 5 and 10 μM for 48 h. LoVo cells were
incubated with NHPI at 5, 10 and 20 μM for 48 h or 72 h. Cell apoptosis was analyzed by flow cytometry using the Annexin V-FITC and PI
double staining. Representative images were presented. b Quantification of flow cytometry analysis of apoptosis. Results were presented as
mean ± SD (n = 3). *p < 0.05, **p < 0.01 and ***p <0.001, difference versus 0 μM control group. c NHPI induced MMP loss in BT-20 cells. BT-20
cells were treated with NHPI at 2.5, 5 and 10 μM for 48 h, stained with JC-1 and subjected to flow cytometry analysis. The dot-plot representation of
the flow cytometry analysis shows the distribution of JC-1 aggregates (cells emitting red fluorescence detected in the FL2 channel) and JC-1
monomers (cells emitting green fluorescence detected in the FL1 channel). d Histograms showing the percentage of JC-1 aggregate-positive
and JC-1 monomer-positive cells. Results were presented as mean ± SD (n = 3). **p < 0.01 and ***p <0.001, difference versus 0 μM control
group. e Effect of NHPI on the expressions of apoptosis-related proteins. Cells were treated with indicated concentrations of NHPI for 24 h,
followed by western blot analysis with indicated antibodies. β-actin was used as a loading control
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at Thr308. It is reported that the nuclear accumulation
of eIF4E occurs in a 4E-BP-dependent manner specific-
ally upon inhibition of mTOR signaling [39]. As shown
in Fig. 5c, treatment of BT-20 cells with NHPI for 6 h
induced the eIF4E nuclear translocation in a
concentration-dependent manner. These results strongly
prove that NHPI suppresses mTORC1 signaling.
mTOR functions as two complexes called mTORC1
and mTORC2. mTORC2 specifically senses growth
factors and regulates proliferation, actin cytoskeleton,
and cell survival [40, 41]. mTORC2 controls several
members of the AGC subfamily of kinases including
Akt, serum- and glucocorticoid-induce protein kinase
1 (SGK1), and protein kinase C-α (PKC-α) [1]. Akt
regulates cellular processes such as survival, apoptosis,
growth, and proliferation through the phosphorylation
of several effectors [1, 11, 42]. Akt phosphorylates and
inhibits tuberous sclerosis complex 2 (TSC2) to acti-
vate signaling through mTORC1 [11]. mTORC2 dir-
ectly activates Akt by phosphorylating its hydrophobic
motif (Ser473), a site required for its maximal
activation [1, 10]. Akt is therefore both an upstream
activator of mTORC1 and a downstream effector of
mTORC2. We then examined whether NHPI had in-
hibitory effect on mTORC2 signaling. Indeed, NHPI
repressed Akt phosphorylation at Ser473, the
mTORC2 target site in BT-20 and LoVo cells (Fig. 5b).
Phosphorylation of mTOR at Ser2481 is indicative of
mTORC2 activation [43]. As shown in Fig. 5b, NHPI
decreased phosphorylation of mTOR at Ser2481 as
well.
Inhibition of mTORC1, such as by rapalogs, blocks the
S6K-mediated negative feedback loops, which further
promote activation of Akt and the MAPK/ERK signaling
cascade, thus promoting cell proliferation, growth, and
survival [15, 24, 25, 27]. Of note, NHPI suppressed
phosphorylation of ERK1/2 in a concentration-
dependent manner in BT-20 and LoVo cells (Fig. 5b).
Taken together, these results demonstrate that NHPI in-
hibits both mTORC1 and mTORC2 signaling and over-
comes feedback activation of Akt and ERK, indicating
that NHPI may achieve a robust anticancer effect.
Fig. 5 NHPI inhibits both mTORC1 and mTORC2 signaling in BT-20 and LoVo cells. a BT-20, LoVo and MDA-MB-231 cells were treated with indicated
concentrations of NHPI for 24 h, followed by western blot analysis with indicated antibodies. β-actin was used as a loading control. b BT-20 and LoVo
cells were treated with indicated concentrations of NHPI for 24 h, followed by western blot analysis with indicated antibodies. β-actin was used as a
loading control. c NHPI induced the eIF4E nuclear translocation in BT-20 cells. BT-20 cells were incubated with indicated concentrations of NHPI for 6 h.
Then the cells were analyzed by immunofluorescence assay labeling with eIF4E antibody and DAPI. eIF4E and nucleus were recognized by the red and
blue fluorescence, respectively
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NHPI inhibits tumor growth in human breast xenografts
in association with suppression of both mTORC1 and
mTORC2 signaling
The in vitro data presented above prompted us to fur-
ther test the antitumor efficacy of NHPI in vivo. Tumor
xenografts were established through subcutaneous in-
oculation with BT-20 cells in nude mice. When tumor
size reached around 100 mm3, tumor-bearing mice were
randomized into two groups and treated daily by intra-
peritoneal injection with 40 mg/kg NHPI or vehicle con-
trol for 53 days. NHPI treatment did not display any
adverse effect on mice body weight in comparison with
control group during the experimental period, indicating
the safety of NHPI (Fig. 6b). However, treatment with
Fig. 6 NHPI inhibits tumor growth in human breast xenografts in association with suppression of both mTORC1 and mTORC2 signaling. 6.8 × 106
BT-20 cells in Matrigel were subcutaneously implanted into nude mice. When tumor size reached around 100 mm3, tumor-bearing mice were
randomized into two groups and treated daily by intraperitoneal injection with 40 mg/kg NHPI or vehicle control for 53 days. a NHPI significantly
inhibited tumor growth in BT-20 xenografts. The individual tumor volume was measured at indicated time (days) and presented as mean ± SE
(n = 9). **p < 0.01 and ***p <0.001, difference versus vehicle-treated control group. b The individual body weight was measured at indicated time
(days) and presented as mean ± SE (n= 9). c Tumors were removed from mice and tumor weight was measured at the end of treatment. Representative
tumor images were shown and tumor weight was presented as mean ± SE (n = 9). *p < 0.05, difference versus vehicle-treated control group.
d NHPI inhibits both mTORC1 and mTORC2 signaling in BT-20 tumor tissues. The phosphorylation levels of mTOR at Ser2448, S6 at Ser235/
236, 4E-BP1 at Ser65 and Akt at Ser473 in tumor tissues were determined by western blot analysis. β-actin was used as a loading control.
e Relative densitometric quantification of protein expression detected in (d). Results were presented as mean ± SE (n = 5). *p < 0.05 and
**p < 0.01, difference versus vehicle-treated control group
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40 mg/kg NHPI resulted in a significant reduction in
both tumor volume (Fig. 6a) and tumor weight (Fig. 6c)
compared with the vehicle control. As shown in Fig. 6a,
NHPI inhibited BT-20 xenografts growth starting from
day 3 of treatment until the end of the study. At the end
of treatment, the average tumor volume of vehicle con-
trol group was approximately 186 mm3 and that of
NHPI-treated group was about 87 mm3, showing a 53 %
tumor growth inhibition (Fig. 6a). Meanwhile, NHPI de-
creased 45 % of tumor weights in BT-20 xenografts,
compared with vehicle control (Fig. 6c). These results
demonstrate that NHPI has potent antitumor activity in
BT-20 xenografts.
To find out whether mTOR signaling was also re-
pressed by NHPI in BT-20 xenografts, tumor tissue ex-
tracts were subjected to western blot analysis. As shown
in Fig. 6d and e, the phosphorylation levels of mTOR at
Ser2448, S6 at Ser235/236, 4E-BP1 at Ser65 and Akt at
Ser473 were significantly decreased in tumors from
NHPI-treated mice. Taken together, these results illus-
trate that NHPI inhibits tumor growth in BT-20 xeno-
grafts in association with its suppression of both
mTORC1 and mTORC2 signaling.
Discussion
The mTOR signaling pathway is one of the major signal-
ing cascades that regulate cell proliferation and survival.
Dysregulation of mTOR signaling pathway is one of the
most commonly observed pathological alterations in hu-
man cancers [11]. The evidence linking activated mTOR
signaling to cancer has generated significant interest in
targeting the pathway for cancer therapy [1, 11]. In the
present study, we found that NHPI selectively inhibited
the proliferation of human breast carcinoma BT-20 cells
and human colon adenocarcinoma LoVo cells, concomi-
tantly suppressing mTOR signaling pathway. However,
no apparent cytotoxicity was observed in NHPI-treated
human normal breast epithelial MCF-10A cells and
other tested cancer cell lines, such as human breast
adenocarcinoma MDA-MB-231 cells. Interestingly,
NHPI at high concentration (20 and 40 μM) did not
affect mTOR signaling in MDA-MB-231 cells. Taken to-
gether, the above results suggest that the selective prolif-
eration inhibitory effect of NHPI may be attributed to
the inhibition of mTOR signaling pathway in these cells.
A plenty of distinct mechanisms including PI3K ampli-
fication/mutation, PTEN loss of function, Akt overex-
pression, and S6K1 or eIF4E overexpression can result
in the constitutive activation of the PI3K/Akt/mTOR
pathway in cancer cells [7]. We speculate that the dis-
tinct mechanisms of mTOR pathway activation in cells
seem to be associated with the sensitivity of different
cells to NHPI. The fact that the antitumor activity of
NHPI is so specific to certain cancer cell lines urged us
to focus on the genetic background of these cell lines.
Notably, all the three NHPI-sensitive cell lines (BT-20,
LoVo and HT-29) harbor mutations of the PI3K p110
catalytic unit, whereas the NHPI-resistant cell lines, such
as human breast adenocarcinoma MDA-MB-231 cells,
lack mutations of the PI3K p110 catalytic unit. Muta-
tions of the PI3K p110 catalytic unit cause increased
PI3K activity that ultimately leads to increased mTOR
signaling pathway activity [44, 45]. Thus, we speculate
that cell lines with high mTOR signaling pathway activ-
ity caused by mutations of the PI3K p110 catalytic unit
are more sensitive to NHPI. However, more studies are
needed to verify the hypothesis and further elucidate the
selective antitumor mechanism of NHPI.
It has been reported that mTOR signaling pathway
regulates cell apoptosis and is involved in the up-
regulation of survivin via rapid changes in mRNA trans-
lation [46, 47]. Our results showed that NHPI induced
apoptosis of BT-20 cells by declining the expressions of
anti-apoptotic proteins survivin and Bcl-xL as well as ac-
tivating of caspase 9 and caspase 3. Considering that
NHPI inhibited mTOR signaling and decreased expres-
sion of anti-apoptotic proteins such as survivin, it is
likely that NHPI-induced apoptosis of BT-20 cells is as-
sociated with the inhibition of mTOR signaling pathway.
Of note, this finding is confirmed in tumors from mice
treated with NHPI. In BT-20 xenografts, NHPI signifi-
cantly inhibited tumor growth. Meanwhile, NHPI re-
duced mTORC1 activation and its substrate 4E-BP1
phosphorylation as well as the phosphorylation level of
Akt at Ser473 in the tumors from NHPI-treated mice,
which further suggests that NHPI displays antitumor ac-
tivity in association with the suppression of both
mTORC1 and mTORC2 signaling pathway.
The recognitions that rapalogs have limited substrate-
specific efficacy and cause feedback activation of several
oncogenic pathways have fostered the development of
ATP-competitive mTOR kinase inhibitors (TKIs) [1, 15,
25–27]. The advantage of TKIs is that they inhibit both
mTORC1 and mTORC2 [48]. Despite the loss of
mTORC2-mediated Ser473 phosphorylation of Akt in
cells treated with TKIs, mTORC1 inhibition would still
promote feedback activation of PI3K-driven phosphoryl-
ation of Akt at Thr308 [3, 15]. Moreover, the loss of
mTORC1-mediated IRS-1 feedback might activate PI3K
effectors other than Akt [15, 49]. These insights have
fueled the development of PI3K and mTOR dual inhibi-
tors. Nevertheless, a recent study showed that NVP-
BEZ235, a PI3K and mTOR dual inhibitor, induced the
activation of the MAPK as indicated by enhanced ERK
phosphorylation, which likely limit the clinical utilization
of it in cancer treatment [50–52]. Our present data
showed that NHPI effectively inhibited mTORC1 and
mTORC2 signaling, and overcame the feedback
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activation of Akt and ERK caused by mTORC1 inhib-
ition in BT-20 and Lovo cells, indicating that NHPI may
achieve a robust anticancer effect.
Conclusions
In conclusion, we found for the first time that NHPI se-
lectively inhibited the proliferation of human breast car-
cinoma BT-20 cells, human colon adenocarcinoma LoVo
and HT-29 cells, and displayed potent antitumor activity
in vivo in BT-20 xenografts. The mechanism by which
NHPI displays antitumor activity is associated with the
inhibition of mTOR signaling pathway. Taken together,
our findings suggest that NHPI may be developed as a
promising candidate for cancer therapeutics by targeting
mTOR signaling pathway.
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